Cargando…
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature
Metastatic pheochromocytoma and paraganglioma (mPHEO/PGL) are frequently associated with succinate dehydrogenase B (SDHB) mutations. Cyclophosphamide-dacarbazine-vincristine (CVD) regimen is recommended as standard chemotherapy for advanced mPHEO/PGL. There is limited evidence to support the role of...
Autores principales: | Tena, Isabel, Gupta, Garima, Tajahuerce, Marcos, Benavent, Marta, Cifrián, Manuel, Falcon, Alejandro, Fonfria, María, del Olmo, Maribel, Reboll, Rosa, Conde, Antonio, Moreno, Francisca, Balaguer, Julia, Cañete, Adela, Palasí, Rosana, Bello, Pilar, Marco, Alfredo, Ponce, José Luis, Merino, Juan Francisco, Llombart, Antonio, Sanchez, Alfredo, Pacak, Karel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922490/ https://www.ncbi.nlm.nih.gov/pubmed/29720885 http://dx.doi.org/10.1177/1179554918763367 |
Ejemplares similares
-
Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
por: Wong, Eric T., et al.
Publicado: (2016) -
Safety and Activity of Metronomic Temozolomide in Second-Line Treatment of Advanced Neuroendocrine Neoplasms
por: Tafuto, Salvatore, et al.
Publicado: (2019) -
Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021) -
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours
por: Koumarianou, Anna, et al.
Publicado: (2012) -
Metronomic temozolomide as second line treatment for metastatic poorly differentiated pancreatic neuroendocrine carcinoma
por: De Divitiis, C., et al.
Publicado: (2016)